Avichezer D, Taylor-Papadimitriou J, Arnon R
Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel.
Cancer Biochem Biophys. 1998 Jun;16(1-2):113-28.
The present study describes the production of a synthetic hexapeptide (DTRPAP)-based anti-mucin (MUC-1) antibody, similar to those produced using either the intact mucin antigen or tumor extracts. This antibody was generated by immunization of rabbits with the synthetic peptide conjugated to bovine serum albumin as a carrier. Using both the ELISA and FACS analysis methods, we have shown that the antibody is reactive with human ovarian and breast cancer cells, but not with normal epithelial breast cells. This antibody is different from the previously reported anti-mucin HMFG-1, HMFG-2 and SM-3 monoclonal antibodies, since competitive experiments with the free synthetic peptide revealed only a 30% inhibition of HMFG-1 binding to the ovarian (OVCAR-3) cancer cells, as compared to 78% inhibition of the anti-synthetic peptide antibody. The peptide was non-inhibitory for HMFG-2, and induced a significant and reproducible stimulation of the SM-3 binding activity to the tumor cells.
本研究描述了一种基于合成六肽（DTRPAP）的抗粘蛋白（MUC-1）抗体的产生，该抗体类似于使用完整粘蛋白抗原或肿瘤提取物产生的抗体。此抗体是通过用与牛血清白蛋白作为载体偶联的合成肽免疫兔子而产生的。使用酶联免疫吸附测定（ELISA）和荧光激活细胞分选（FACS）分析方法，我们已表明该抗体可与人卵巢癌细胞和乳腺癌细胞发生反应，但与正常乳腺上皮细胞无反应。该抗体不同于先前报道的抗粘蛋白HMFG-1、HMFG-2和SM-3单克隆抗体，因为与游离合成肽的竞争性实验显示，HMFG-1与卵巢（OVCAR-3）癌细胞结合的抑制率仅为30%，而抗合成肽抗体的抑制率为78%。该肽对HMFG-2无抑制作用，且可显著且可重复地刺激SM-3与肿瘤细胞的结合活性。
